If MUC1 can be shown as a correlative biomarker, as our data suggests, we may alleviate some of the complications associated with anti-TGF-β therapies, especially in SMAD4 independent PDA cases. The gene discussed is TGFB1; the disease is Patent ductus arteriosus.